NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PERMITIL (fluphenazine hydrochloride) by Merck & Co. is clinical pharmacology fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. Approved for the management of manifestations of psychotic disorders. First approved in 1960.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERMITIL (fluphenazine hydrochloride) is an oral extended-release antipsychotic tablet approved in 1960 for managing psychotic disorder manifestations. It acts across multiple CNS levels and organ systems, though its precise therapeutic mechanism remains incompletely understood. This is a first-generation antipsychotic with decades of clinical use in schizophrenia and related conditions.
LOE Approaching
LOE-approaching lifecycle indicates declining revenue trajectory; brand team focus shifting toward cost management and market consolidation rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. The mechanism whereby its therapeutic action is exerted is unknown.
Indications (1)
Career Relevance
Working on PERMITIL offers limited career advancement due to its LOE-approaching lifecycle and minimal commercial growth trajectory. Roles on this product are primarily defensive and operational, focusing on market maintenance and generic transition rather than strategic innovation or market expansion.
Worked on PERMITIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.